glp 1 weight loss drugs Rx Trends: Real-World Data on GLP-1s for GLP-1 weight-loss drugs: PA, NJ

Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC

Oral formulations of calcitonin 10 , octreotide 11 and insulin 12 with permeation enhancers have all been tested in clinical studies up to phase 3 and detailed pharmacokinetics have been established

These agents protect cells from inflammatory harm by reducing oxidative stress and supporting tissue equilibrium

Second, a large percentage of patients had multiple reasons for discontinuation in their notes

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

C., Stensen S., et al